Evidence map›Paper›PMID 39839457›Full record

ReviewInternational journal of nanomedicine2025

Application of Multifunctional Metal Nanoparticles in the Treatment of Glioma.

Yanhong Ren, Han Yang, Duo Xu, Zhengkui Zhang, Shangfeng Gao, Rutong Yu

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Glioma Cell Membrane-Coated CaCOInternational journal of nanomedicine · 2026
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanhong Ren *Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.ORCID 0000-0001-7494-9137
Han Yang *Department of Neurology, The First Hospital of Changsha, Changsha, 410008, People's Republic of China.
Duo XuInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.
Zhengkui ZhangInstitute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.
Shangfeng GaoDepartment of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.
Rutong YuDepartment of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent. Nanotechnology, with its excellent biocompatibility and controllable chemical properties, has attracted much attention in recent decades. Metal nanoparticles are widely used in the field of biomedical imaging and detection, and have shown promising applications in targeted drug delivery and therapy. The current review aims to systematically summarize the application of different types of metal nanoparticles in the treatment and detection of glioma. We also discussed the advantages and mechanisms of metal nanoparticles when used for glioma therapy, including chemotherapy, radiotherapy and photothermal therapy. We hope to promote the application of metallic nanoparticles in glioma diagnosis and treatment, moving towards clinical translation to benefit patients.

Indexed as

Brain NeoplasmsGliomaMetal NanoparticlesMultifunctional NanoparticlesAnimalsAntineoplastic AgentsDrug Delivery SystemsHumansAntineoplastic Agentsgliomametal nanoparticlestreatment

Identifiers

PMID39839457
PMCPMC11748046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.